## Recombinant Human S100-A8\&S100-A9 Protein

## Catalog No.: RP01253 Recombinant

## Sequence Information

| Species | Gene ID | Swiss Prot |
| :--- | :--- | :--- |
| Human | $6279 \& 6280$ | P05109/P067 |
|  |  | 02 |

## Tags

C-His(S100A8)\&No tag(S100A9)

## Synonyms

CAGA;CAGB;CFAG;MRP14;MRP8\&S100A9
;S100A8;Calprotectin;S100A8\&S100A9

## Product Information

## Source Purification

Baculovirus-Infected $>95 \%$ by SDS-PAGE. Sf9 Cells

## Endotoxin

< 1.0 EU/ $\mu \mathrm{g}$ of the protein by LAL method.

## Formulation

Lyophilized from a $0.22 \mu \mathrm{~m}$ filtered solution of PBS,1mM DTT, pH 7.4.Contact us for customized product form or formulation.

## Reconstitution

Centrifuge the vial before opening. Reconstitute to a concentration of $0.1-0.5 \mathrm{mg} / \mathrm{mL}$ in sterile distilled water. Avoid votex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1\% BSA, 5\% HSA, 10\% FBS or 5\% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

## Contact

| $\mathbf{0}$ | $400-999-6126$ |
| ---: | ---: |
| $\boldsymbol{c}$ | cn.market@abclonal.com.cn |
| $\boldsymbol{c}$ | www.abclonal.com.cn |

## Background

## Basic Information

## Description

Recombinant Human S100-A8\&S100-A9 Protein is produced by Baculovirus-Infected Sf9 Cells expression system. The target protein is expressed with sequence (Met1-Glu93\&Met1-Pro114) of human S100A8\&S100A9 Heterodimer (Accession \#NP_002955.2/NP_002956.1) fused with a $6 \times$ His tag at the C-terminus(S100A8).

## Bio-Activity

## Storage

Store the lyophilized protein at $-20^{\circ} \mathrm{C}$ to $-80^{\circ} \mathrm{C}$ for long term.
After reconstitution, the protein solution is stable at $-20^{\circ} \mathrm{C}$ for 3 months, at $2-8{ }^{\circ} \mathrm{C}$ for up to 1 week.
Avoid repeated freeze/thaw cycles.


Recombinant Human S100-A8\&S100-A9 Protein was determined by SDS-PAGE with Coomassie Blue, showing bands at 13 kDa and 14 kDa .

